Cargando…

The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation

Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical a...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez Palomo, Ana Belen, Lucas, Michaela, Dilley, Rodney J., McLenachan, Samuel, Chen, Fred Kuanfu, Requena, Jordi, Sal, Marti Farrera, Lucas, Andrew, Alvarez, Inaki, Jaraquemada, Dolores, Edel, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449681/
https://www.ncbi.nlm.nih.gov/pubmed/26237380
http://dx.doi.org/10.3390/jcm3020373
_version_ 1782373899171790848
author Alvarez Palomo, Ana Belen
Lucas, Michaela
Dilley, Rodney J.
McLenachan, Samuel
Chen, Fred Kuanfu
Requena, Jordi
Sal, Marti Farrera
Lucas, Andrew
Alvarez, Inaki
Jaraquemada, Dolores
Edel, Michael J.
author_facet Alvarez Palomo, Ana Belen
Lucas, Michaela
Dilley, Rodney J.
McLenachan, Samuel
Chen, Fred Kuanfu
Requena, Jordi
Sal, Marti Farrera
Lucas, Andrew
Alvarez, Inaki
Jaraquemada, Dolores
Edel, Michael J.
author_sort Alvarez Palomo, Ana Belen
collection PubMed
description Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues.
format Online
Article
Text
id pubmed-4449681
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44496812015-07-28 The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation Alvarez Palomo, Ana Belen Lucas, Michaela Dilley, Rodney J. McLenachan, Samuel Chen, Fred Kuanfu Requena, Jordi Sal, Marti Farrera Lucas, Andrew Alvarez, Inaki Jaraquemada, Dolores Edel, Michael J. J Clin Med Review Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues. MDPI 2014-04-04 /pmc/articles/PMC4449681/ /pubmed/26237380 http://dx.doi.org/10.3390/jcm3020373 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Alvarez Palomo, Ana Belen
Lucas, Michaela
Dilley, Rodney J.
McLenachan, Samuel
Chen, Fred Kuanfu
Requena, Jordi
Sal, Marti Farrera
Lucas, Andrew
Alvarez, Inaki
Jaraquemada, Dolores
Edel, Michael J.
The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
title The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
title_full The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
title_fullStr The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
title_full_unstemmed The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
title_short The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
title_sort power and the promise of cell reprogramming: personalized autologous body organ and cell transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449681/
https://www.ncbi.nlm.nih.gov/pubmed/26237380
http://dx.doi.org/10.3390/jcm3020373
work_keys_str_mv AT alvarezpalomoanabelen thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT lucasmichaela thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT dilleyrodneyj thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT mclenachansamuel thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT chenfredkuanfu thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT requenajordi thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT salmartifarrera thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT lucasandrew thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT alvarezinaki thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT jaraquemadadolores thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT edelmichaelj thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT alvarezpalomoanabelen powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT lucasmichaela powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT dilleyrodneyj powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT mclenachansamuel powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT chenfredkuanfu powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT requenajordi powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT salmartifarrera powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT lucasandrew powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT alvarezinaki powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT jaraquemadadolores powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation
AT edelmichaelj powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation